Immunotoxins

New therapeutic reagents for autoimmunity, cancer, and AIDS

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Immunotoxins consist of cell-reactive ligands coupled to toxins or their toxic subunits. The ligands are usually antibodies, hormones, or growth factors and the toxins are of bacterial or plant origin. In vitro studies using A chain-containing immunotoxins specifically to kill tumor cells were successful and led to further experiments in vivo. Such studies, carried out over the past 5 years in both animals and humans, have demonstrated that the efficacy of immunotoxins in vivo is often poor, due to problems involving instability of the conjugate, inferior potency, inaccessibility of tumor cells, nonspecific binding to cells other than the target cells, and survival of antigen-negative mutants. In addition, immune responses against both the ligand and the A chain are usually elicited, precluding repeated therapy. During the past several years, there have been attempts to solve these problems and develop more effective immunotoxins.

Original languageEnglish (US)
JournalJournal of Clinical Immunology
Volume10
Issue number6 Supplement
DOIs
StatePublished - Nov 1990

Fingerprint

Immunotoxins
Autoimmunity
Acquired Immunodeficiency Syndrome
Ligands
Neoplasms
Bacterial Toxins
Poisons
Therapeutics
Cell Survival
Intercellular Signaling Peptides and Proteins
Hormones
Antigens
Antibodies

Keywords

  • Immunotoxin (IT)
  • monoclonal antibodies (mAbs)
  • ricin A chain (A chain)

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Immunotoxins : New therapeutic reagents for autoimmunity, cancer, and AIDS. / Vitetta, Ellen S.

In: Journal of Clinical Immunology, Vol. 10, No. 6 Supplement, 11.1990.

Research output: Contribution to journalArticle

@article{27f899a7a091469aadba24cc4e7ec691,
title = "Immunotoxins: New therapeutic reagents for autoimmunity, cancer, and AIDS",
abstract = "Immunotoxins consist of cell-reactive ligands coupled to toxins or their toxic subunits. The ligands are usually antibodies, hormones, or growth factors and the toxins are of bacterial or plant origin. In vitro studies using A chain-containing immunotoxins specifically to kill tumor cells were successful and led to further experiments in vivo. Such studies, carried out over the past 5 years in both animals and humans, have demonstrated that the efficacy of immunotoxins in vivo is often poor, due to problems involving instability of the conjugate, inferior potency, inaccessibility of tumor cells, nonspecific binding to cells other than the target cells, and survival of antigen-negative mutants. In addition, immune responses against both the ligand and the A chain are usually elicited, precluding repeated therapy. During the past several years, there have been attempts to solve these problems and develop more effective immunotoxins.",
keywords = "Immunotoxin (IT), monoclonal antibodies (mAbs), ricin A chain (A chain)",
author = "Vitetta, {Ellen S.}",
year = "1990",
month = "11",
doi = "10.1007/BF00918687",
language = "English (US)",
volume = "10",
journal = "Journal of Clinical Immunology",
issn = "0271-9142",
publisher = "Springer New York",
number = "6 Supplement",

}

TY - JOUR

T1 - Immunotoxins

T2 - New therapeutic reagents for autoimmunity, cancer, and AIDS

AU - Vitetta, Ellen S.

PY - 1990/11

Y1 - 1990/11

N2 - Immunotoxins consist of cell-reactive ligands coupled to toxins or their toxic subunits. The ligands are usually antibodies, hormones, or growth factors and the toxins are of bacterial or plant origin. In vitro studies using A chain-containing immunotoxins specifically to kill tumor cells were successful and led to further experiments in vivo. Such studies, carried out over the past 5 years in both animals and humans, have demonstrated that the efficacy of immunotoxins in vivo is often poor, due to problems involving instability of the conjugate, inferior potency, inaccessibility of tumor cells, nonspecific binding to cells other than the target cells, and survival of antigen-negative mutants. In addition, immune responses against both the ligand and the A chain are usually elicited, precluding repeated therapy. During the past several years, there have been attempts to solve these problems and develop more effective immunotoxins.

AB - Immunotoxins consist of cell-reactive ligands coupled to toxins or their toxic subunits. The ligands are usually antibodies, hormones, or growth factors and the toxins are of bacterial or plant origin. In vitro studies using A chain-containing immunotoxins specifically to kill tumor cells were successful and led to further experiments in vivo. Such studies, carried out over the past 5 years in both animals and humans, have demonstrated that the efficacy of immunotoxins in vivo is often poor, due to problems involving instability of the conjugate, inferior potency, inaccessibility of tumor cells, nonspecific binding to cells other than the target cells, and survival of antigen-negative mutants. In addition, immune responses against both the ligand and the A chain are usually elicited, precluding repeated therapy. During the past several years, there have been attempts to solve these problems and develop more effective immunotoxins.

KW - Immunotoxin (IT)

KW - monoclonal antibodies (mAbs)

KW - ricin A chain (A chain)

UR - http://www.scopus.com/inward/record.url?scp=0025615069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025615069&partnerID=8YFLogxK

U2 - 10.1007/BF00918687

DO - 10.1007/BF00918687

M3 - Article

VL - 10

JO - Journal of Clinical Immunology

JF - Journal of Clinical Immunology

SN - 0271-9142

IS - 6 Supplement

ER -